Clinical trials: Inflammation; Skin
Atopic Dermatitis
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
The purpose for this study is to assess the Safety and Efficacy of Daily Application for 4 weeks of DBI-001 Gel Versus Aqueous Gel in Subjects with Atopic Dermatitis
- Trial name
- NCT05253755
- Testing
- DBI-001, Aqueous gel
- Where
- 3 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01339091
- Testing
- Dalbavancin, Vancomycin / Linezolid
- Where
- 91 sites in United States, Canada and 6 more
- Volunteers
- 573 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Pruritus, Atopic Dermatitis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
- Trial name
- ATOMIK (NCT02975206)
- Testing
- Serlopitant High Dose, Serlopitant Low Dose
- Where
- 52 sites in United States
- Volunteers
- 484 people
- Sponsor
- Vyne Therapeutics Inc.
Allergic Contact Dermatitis
Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
Nickel (Ni)-mediated allergic contact dermatitis (ACD) is a very common disease worldwide. Our previous findings demonstrated that in vitro supplementation of polyphenols, extracted from seeds of red grape (Nero di Troia…
- Trial name
- Grapolyphen (NCT03902392)
- Testing
- NaturOx Group (A)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Bari
Psoriatic Arthritis
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated…
- Trial name
- NCT01818804
- Testing
- n-3PUFA, olive oil
- Where
- 2 sites in Denmark
- Volunteers
- 145 people
- Sponsor
- Aalborg University Hospital
Eczema
Blue Light for Treating Eczema
Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of treatment with 453nm blue light with no treatment in patients with Eczema.
- Trial name
- NCT02002871
- Testing
- PSO-CT02 device
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Philips Electronics Nederland BV
Psoriatic Arthritis
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis.
- Trial name
- PALACE2 (NCT01212757)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 98 sites in United States, Belgium and 14 more
- Volunteers
- 488 people
- Sponsor
- Amgen
Atopic Dermatitis
VANOS Cream and Skin Barrier Function
The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis.
- Trial name
- NCT00819507
- Testing
- Fluocinonide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Dermatitis, Atopic
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
- Trial name
- AtDvance (NCT06447506)
- Testing
- GSK1070806
- Where
- 51 sites in United States, Argentina and 13 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Type 2 Diabetes
Exercise and Pioglitazone for HIV-Metabolic Syndromes
The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d) with and without aerobic and strength exercise training for reducing glucose intolerance and central adiposity in HIV-infected people.
- Conditions
- HIV Infections, Type 2 Diabetes, Obesity, HIV
- Trial name
- NCT00639457
- Testing
- Pioglitazone, Exercise training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Atopic Dermatitis
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT05911841
- Testing
- LY3454738
- Where
- 66 sites in United States, Canada and 7 more
- Volunteers
- 234 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement.
- Trial name
- NCT05127421
- Testing
- Ruxolitinib cream, Vehicle
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine…
- Trial name
- BREEZE-AD4 (NCT03428100)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 103 sites in Austria, Belgium and 12 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
- Trial name
- NCT03745638
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 631 people
- Sponsor
- Incyte Corporation
Lupus Erythematosus, Systemic, Musculoskeletal Pain
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms.
- Trial name
- NCT02822989
- Testing
- Vagus nerve stimulation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwell Health
Dermatitis, Atopic
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.
- Trial name
- NCT01652885
- Testing
- AN2728 Topical Ointment, 2%
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Atopic Dermatitis Eczema
Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections.
- Trial name
- NCT03158012
- Testing
- Autologous Microbial Transplant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Diego
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
- Trial name
- NCT04773600
- Testing
- Roflumilast Cream, Vehicle cream
- Where
- 53 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis, Atopic Dermatitis
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic…
- Trial name
- NCT01137032
- Testing
- Pandel Cream 0.1%
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Fougera Pharmaceuticals Inc.